Octagon Capital Advisors LP
Filing Date
Global Rank
#1,870
/ 8,622
▲ 271
· as of Mar 2026
Top Industry
Biotechnology
96.3%
3Y Alpha vs SPY
+14.2%
Period ended 4 months ago
Filed May 15, 2026 · 3mo
22 quarters · since Dec 2020
Clone Performance
Jul 2023–Jul 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Cloned portfolio
+134.6%
SPY
+67.9%
Annualised alpha
+14.0%
Max drawdown
−56.0%
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. It tracks 97% of reported value on average across 13 quarters. Past performance does not predict future results.
Portfolio Concentration
29 tracked positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
18.1%
+4.5 pts
Top 5
48.4%
−1.7 pts
Top 10
68.6%
−4.5 pts
HHI
726
Diversified−2
Portfolio Trend
22 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $903,609,411 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
6 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| PALI | Palisade Bio, Inc. | +708,419 | 10,276,317 | $17,983,554 | |
| OCUL | Ocular Therapeutix, Inc | +543,000 | 3,166,600 | $26,821,102 | |
| DTIL | Precision Biosciences Inc | +318,737 | 2,236,732 | $12,302,026 | |
| ALMS | Alumis Inc. | +300,000 | 2,830,700 | $62,360,321 | |
| KALV | KalVista Pharmaceuticals, Inc. | +176,667 | 1,450,000 | $29,188,500 | |
| BIOA | BioAge Labs, Inc. | +150,000 | 1,748,000 | $30,572,520 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
9 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | −6,165,371 | 7,750,000 | $2,549,750 | |
| TRVI | Trevi Therapeutics, Inc. | −1,330,000 | 1,485,000 | $17,716,050 | |
| LXEO | Lexeo Therapeutics, Inc. | −625,000 | 1,100,000 | $6,314,000 | |
| PHVS | Pharvaris N.V. | −506,465 | 165,000 | $4,661,250 | |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | −470,000 | 1,946,667 | $163,364,294 | |
| EVMN | Evommune, Inc. | −356,528 | 143,472 | $3,298,421 | |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | −324,110 | 719,000 | $6,435,050 | |
| KYMR | Kymera Therapeutics, Inc. | −110,000 | 425,000 | $35,398,250 | |
| ABVX | Abivax S.A. | −79,000 | 677,000 | $75,383,950 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
8 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | 2,440,000 | $46,116,000 | |
| MIRM | Mirum Pharmaceuticals, Inc. | 338,900 | $31,307,582 | |
| XENE | Xenon Pharmaceuticals Inc. | 490,000 | $28,493,500 | |
| TERN | Terns Pharmaceuticals, Inc. | 530,000 | $27,941,600 | |
| IRON | Disc Medicine, Inc. | 270,000 | $17,263,800 | |
| AKTS | Aktis Oncology, Inc. | 960,847 | $17,189,552 | |
| CNTX | Context Therapeutics Inc. | 5,250,000 | $13,755,000 | |
| CATX | Perspective Therapeutics, Inc. | 791,555 | $3,300,784 | |
| No positions match the current search. | ||||
29 tracked positions ·
$903,609,411 total
· filing declares
29 positions · $903,605,540
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Reduced | 1,946,667 | $163,364,294 | 18.08% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Held | 2,350,000 | $90,451,500 | 10.01% | |
| ABVX |
Abivax S.A.
Healthcare
|
Reduced | 677,000 | $75,383,950 | 8.34% | |
| ALMS |
Alumis Inc.
Healthcare
|
Added | 2,830,700 | $62,360,321 | 6.90% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
NEW | 2,440,000 | $46,116,000 | 5.10% | |
| AVBP |
ArriVent BioPharma, Inc.
Healthcare
|
Held | 1,971,054 | $45,472,215 | 5.03% | |
| TSHA |
Taysha Gene Therapies, Inc.
Healthcare
|
Held | 8,859,911 | $39,603,802 | 4.38% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Reduced | 425,000 | $35,398,250 | 3.92% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
NEW | 338,900 | $31,307,582 | 3.46% | |
| BIOA |
BioAge Labs, Inc.
Healthcare
|
Added | 1,748,000 | $30,572,520 | 3.38% | |
| CNTA |
Centessa Pharmaceuticals plc
Healthcare
|
Held | 750,000 | $29,790,000 | 3.30% | |
| KALV |
KalVista Pharmaceuticals, Inc.
Healthcare
|
Added | 1,450,000 | $29,188,500 | 3.23% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
NEW | 490,000 | $28,493,500 | 3.15% | |
| TERN |
Terns Pharmaceuticals, Inc.
Healthcare
|
NEW | 530,000 | $27,941,600 | 3.09% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
Added | 3,166,600 | $26,821,102 | 2.97% | |
| PALI |
Palisade Bio, Inc.
Healthcare
|
Added | 10,276,317 | $17,983,554 | 1.99% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
Reduced | 1,485,000 | $17,716,050 | 1.96% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
NEW | 270,000 | $17,263,800 | 1.91% | |
| AKTS |
Aktis Oncology, Inc.
Healthcare
|
NEW | 960,847 | $17,189,552 | 1.90% | |
| CNTX |
Context Therapeutics Inc.
Healthcare
|
NEW | 5,250,000 | $13,755,000 | 1.52% | |
| DTIL |
Precision Biosciences Inc
Healthcare
|
Reduced | 2,236,732 | $12,302,026 | 1.36% | |
| DBVT |
DBV Technologies S.A.
Healthcare
|
Held | 574,200 | $11,995,038 | 1.33% | |
| UNCY |
Unicycive Therapeutics, Inc.
Healthcare
|
Reduced | 1,000,000 | $6,580,000 | 0.73% | |
| BBOT |
BridgeBio Oncology Therapeutics, Inc.
Healthcare
|
Reduced | 719,000 | $6,435,050 | 0.71% | |
| LXEO |
Lexeo Therapeutics, Inc.
Healthcare
|
Reduced | 1,100,000 | $6,314,000 | 0.70% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Reduced | 165,000 | $4,661,250 | 0.52% | |
| CATX |
Perspective Therapeutics, Inc.
Healthcare
|
NEW | 791,555 | $3,300,784 | 0.37% | |
| EVMN |
Evommune, Inc.
Healthcare
|
Reduced | 143,472 | $3,298,421 | 0.37% | |
| GOSS |
Gossamer Bio, Inc.
Healthcare
|
Reduced | 7,750,000 | $2,549,750 | 0.28% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.